Stay updated with breaking news from Probenecid Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipelinePH94B Phase 3 program for social anxiety disorder advancing towards important next stepsPH10 Phase 1 study initiated to facilitate plans for Phase 2B develo...
07.02.2023 - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update ...
Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 beginsPreliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD)SOUTH...